Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiska medel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydroklorid - multipel skleros, skovvis förlöpande - immunsuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 och 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - imatinibmesilat - filmdragerad tablett - 100 mg - imatinibmesilat 119,5 mg aktiv substans - imatinib

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - imatinibmesilat - filmdragerad tablett - 400 mg - imatinibmesilat 478 mg aktiv substans - imatinib

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan hospital as - bortezomib - pulver till injektionsvätska, lösning - 3,5 mg - mannitol hjälpämne; bortezomib 3,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - kaptopril - tablett - 12,5 mg - kaptopril 12,5 mg aktiv substans; laktos (vattenfri) hjälpämne - kaptopril

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - lantan(iii)karbonatoktahydrat - tuggtablett - 750 mg - lantan(iii)karbonatoktahydrat 1605,028 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - lantan(iii)karbonatoktahydrat - tuggtablett - 500 mg - lantan(iii)karbonatoktahydrat 1070,019 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - lantan(iii)karbonatoktahydrat - tuggtablett - 1000 mg - lantan(iii)karbonatoktahydrat 2140,037 mg aktiv substans